BR112018017194A2 - vetor, célula cancerosa ou célula imune, e, medicamento. - Google Patents
vetor, célula cancerosa ou célula imune, e, medicamento.Info
- Publication number
- BR112018017194A2 BR112018017194A2 BR112018017194A BR112018017194A BR112018017194A2 BR 112018017194 A2 BR112018017194 A2 BR 112018017194A2 BR 112018017194 A BR112018017194 A BR 112018017194A BR 112018017194 A BR112018017194 A BR 112018017194A BR 112018017194 A2 BR112018017194 A2 BR 112018017194A2
- Authority
- BR
- Brazil
- Prior art keywords
- vector
- 1bbl
- cancer
- cell
- medicine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000002865 immune cell Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Manufacturing & Machinery (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente revelação fornece um vetor novo para imunoestimulação e métodos de uso do mesmo em imunoterapia, em particular em imunoterapia de câncer. o vetor novo compreende sequências de ácidos nucleicos que codificam o ligante de 4-1bb (4-1bbl, ligante de cd137), il-12 de cadeia única (sc-il-12, ?single chain il-12?) e il-2, sendo que o vetor fornece uma expressão aumentada de 4-1bbl em comparação com os níveis de expressão de sc-il-12 e de il-2. especificamente, as sequências de ácidos nucleicos que codificam 4-1bbl, sc-il-12 e il-2 estão organizadas no vetor na orientação de 5? para 3? em uma ordem sequencial 1, 2, 3, desde que o gene que codifica sc-il-12 não esteja na posição 1. as modalidades da presente revelação incluem partículas virais compreendendo o vetor novo e, também, células canceroras ou imunes transduzidas ou transfectadas com o vetor novo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16157423.1A EP3211000B1 (en) | 2016-02-25 | 2016-02-25 | Novel immunostimulating vector system |
PCT/EP2017/054216 WO2017144602A1 (en) | 2016-02-25 | 2017-02-23 | Novel immunostimulating vector system |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018017194A2 true BR112018017194A2 (pt) | 2019-01-02 |
Family
ID=55446663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018017194A BR112018017194A2 (pt) | 2016-02-25 | 2017-02-23 | vetor, célula cancerosa ou célula imune, e, medicamento. |
Country Status (14)
Country | Link |
---|---|
US (2) | US10994027B2 (pt) |
EP (2) | EP3211000B1 (pt) |
JP (1) | JP6698881B2 (pt) |
KR (1) | KR20180135441A (pt) |
CN (1) | CN109311958A (pt) |
AU (1) | AU2017222226B2 (pt) |
BR (1) | BR112018017194A2 (pt) |
CA (1) | CA3015247C (pt) |
EA (1) | EA201891681A1 (pt) |
ES (2) | ES2718192T3 (pt) |
IL (1) | IL261248A (pt) |
MA (1) | MA43676A (pt) |
MX (1) | MX2018010172A (pt) |
WO (1) | WO2017144602A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4186518A1 (en) | 2016-05-18 | 2023-05-31 | ModernaTX, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
WO2019107929A1 (ko) | 2017-11-28 | 2019-06-06 | 주식회사 엘지화학 | 소결 자석의 제조 방법 및 소결 자석 |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
EP3927833A4 (en) * | 2019-02-21 | 2022-11-30 | Unleash Immuno Oncolytics, Inc. | ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
EP4153745A1 (en) | 2020-05-17 | 2023-03-29 | Boehringer Ingelheim International GmbH | Viral vectors and nucleic acids for regulated gene therapy |
IL301749A (en) * | 2020-09-29 | 2023-05-01 | Neuexcell Therapeutics Inc | Neuro vector D1 |
WO2022212896A1 (en) * | 2021-04-02 | 2022-10-06 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
US6093700A (en) * | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
US6034072A (en) * | 1997-02-10 | 2000-03-07 | Genemedicine, Inc. | IL-2 gene expression and delivery systems and uses |
WO2003006632A2 (en) * | 2001-07-12 | 2003-01-23 | Canvac | Methods and compisitions for activation human t cells in vitro |
ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
DE10248141B4 (de) * | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
US20040071385A1 (en) | 2002-10-15 | 2004-04-15 | Lee Bruce W. | PCB incorporating integral optical layers |
US8809017B2 (en) * | 2011-05-24 | 2014-08-19 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
-
2016
- 2016-02-25 EP EP16157423.1A patent/EP3211000B1/en active Active
- 2016-02-25 ES ES16157423T patent/ES2718192T3/es active Active
-
2017
- 2017-02-23 MX MX2018010172A patent/MX2018010172A/es unknown
- 2017-02-23 ES ES17706998T patent/ES2901008T3/es active Active
- 2017-02-23 WO PCT/EP2017/054216 patent/WO2017144602A1/en active Application Filing
- 2017-02-23 AU AU2017222226A patent/AU2017222226B2/en active Active
- 2017-02-23 JP JP2018563758A patent/JP6698881B2/ja active Active
- 2017-02-23 US US16/079,331 patent/US10994027B2/en active Active
- 2017-02-23 CA CA3015247A patent/CA3015247C/en active Active
- 2017-02-23 KR KR1020187027405A patent/KR20180135441A/ko not_active Application Discontinuation
- 2017-02-23 BR BR112018017194A patent/BR112018017194A2/pt unknown
- 2017-02-23 MA MA043676A patent/MA43676A/fr unknown
- 2017-02-23 EP EP17706998.6A patent/EP3419995B1/en active Active
- 2017-02-23 EA EA201891681A patent/EA201891681A1/ru unknown
- 2017-02-23 CN CN201780025515.9A patent/CN109311958A/zh active Pending
-
2018
- 2018-08-20 IL IL261248A patent/IL261248A/en unknown
-
2021
- 2021-04-01 US US17/220,578 patent/US20210220486A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190046664A1 (en) | 2019-02-14 |
EP3419995A1 (en) | 2019-01-02 |
EA201891681A1 (ru) | 2019-04-30 |
CA3015247A1 (en) | 2017-08-31 |
AU2017222226A1 (en) | 2018-09-13 |
US20210220486A1 (en) | 2021-07-22 |
MA43676A (fr) | 2018-11-28 |
ES2718192T3 (es) | 2019-06-28 |
CA3015247C (en) | 2021-12-07 |
EP3211000A1 (en) | 2017-08-30 |
KR20180135441A (ko) | 2018-12-20 |
EP3419995B1 (en) | 2021-09-15 |
US10994027B2 (en) | 2021-05-04 |
MX2018010172A (es) | 2019-05-22 |
WO2017144602A1 (en) | 2017-08-31 |
JP2019509760A (ja) | 2019-04-11 |
CN109311958A (zh) | 2019-02-05 |
AU2017222226B2 (en) | 2020-10-08 |
IL261248A (en) | 2018-10-31 |
ES2901008T3 (es) | 2022-03-21 |
JP6698881B2 (ja) | 2020-05-27 |
EP3211000B1 (en) | 2019-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018017194A2 (pt) | vetor, célula cancerosa ou célula imune, e, medicamento. | |
MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
BR112018074325A2 (pt) | anticorpo para ligação a receptor de interleucina 4 | |
BR112012028805A2 (pt) | composições de endorribonuclease e métodos de uso das mesmas. | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
MX2020010461A (es) | Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados. | |
BR112019006388A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
EA201990861A1 (ru) | Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения | |
MX2021001158A (es) | Vector hsv oncolitico. | |
BR112016030424A2 (pt) | construções de anticorpo multiespecíficas | |
BR112017008976A2 (pt) | ?composição, métodos de aumento da viscosidade de composições aquosas, de tratamento de material, de produção de dextrano e reação enzimática? | |
MX2016015952A (es) | Constructos de anticuerpo multiespecifico. | |
CO6270367A2 (es) | Genes de dc-sign icam-3 y lsectin porcinas y usos de los mismos | |
BRPI0814781A8 (pt) | ''proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico descarboxilase'' | |
BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
BR112017008827A2 (pt) | célula recombinante cho, cultura em larga escala, e, composição. | |
BR112018069823A2 (pt) | molécula de dna, vetor, célula hospedeira, composição, molécula de rna, molécula de ácido nucleico, composição farmacêutica, kit, e, uso de uma utr | |
BR112013017363A2 (pt) | biblioteca de alphabody de cadeia única, mistura de bibliotecas de alphabody, ácido nucleico ou biblioteca de vetor, biblioteca de células hospedeiras, uso de uma biblioteca de alphabody de cadeia única, método para a produção de uma biblioteca de alphabody de cadeia única, método para a produção de um ou mais polipeptídeos de alphabody de cadeia única, polipeptíceo de alphabody de cadeia única, ácido nucleico, vetor e célula hospedeira | |
BR112015005604A2 (pt) | vetores de expressão compreendendo sequências de potencializador e promotor de citomegalovírus quimérico | |
BR112016023688A2 (pt) | célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada | |
BR112016025898A2 (pt) | ?drimenol sintases e método para produzir drimenol? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |